According to Livingstone Health, the innovation improves surgical outcomes and lowers medical costs, as it significantly reduces post-surgery complications compared to traditional procedures such as bone grafting and permanent implants.
Catalist-listed Livingstone Health has signed a memorandum of understanding (MOU) with Australian Securities Exchange (ASX)-listed Osteopore to further develop the utilisation of 3D-printed micro-structures for bone and tissue healing and regeneration.
The MOU will combine the expertise of Livingstone Health’s orthopaedic surgeons and Osteopore’s innovations in natural tissue regeneration. Some of the latter’s innovations include bioresorbable implants made from patented scaffolds that are 3D-printed. These scaffolds dissolve naturally over time and leaves only natural, healthy bone tissue.
